Editas Medicine reports 90% cholesterol reductions in primate study

May 26, 2026 6:01 AM

Editas Medicine Inc. (NASDAQ: EDIT) presented preclinical data showing its gene editing treatment EDIT-401 achieved approximately 90% reductions in LDL ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found